Carnegie Investment Counsel Has $49.83 Million Stake in Zoetis Inc. $ZTS

Carnegie Investment Counsel lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 340,532 shares of the company’s stock after acquiring an additional 21,563 shares during the quarter. Zoetis makes up about 0.9% of Carnegie Investment Counsel’s portfolio, making the stock its 23rd biggest holding. Carnegie Investment Counsel’s holdings in Zoetis were worth $49,827,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Howard Capital Management Group LLC boosted its position in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 106,092 shares of the company’s stock worth $15,523,000 after purchasing an additional 815 shares during the period. New Hampshire Trust lifted its stake in shares of Zoetis by 5.3% during the 3rd quarter. New Hampshire Trust now owns 10,281 shares of the company’s stock worth $1,504,000 after buying an additional 514 shares during the last quarter. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the period. Capital Advisors Ltd. LLC boosted its holdings in shares of Zoetis by 45.7% during the 3rd quarter. Capital Advisors Ltd. LLC now owns 1,371 shares of the company’s stock worth $201,000 after buying an additional 430 shares during the period. Finally, Ellsworth Advisors LLC grew its stake in Zoetis by 10.2% in the 3rd quarter. Ellsworth Advisors LLC now owns 12,618 shares of the company’s stock valued at $1,793,000 after buying an additional 1,163 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZTS. UBS Group cut their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a research note on Monday, December 15th. Morgan Stanley set a $160.00 price target on Zoetis in a research note on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Finally, KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $160.18.

Zoetis Trading Up 0.5%

Shares of NYSE:ZTS opened at $126.16 on Friday. The business’s 50 day simple moving average is $127.05 and its 200 day simple moving average is $143.14. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The company has a market capitalization of $55.60 billion, a P/E ratio of 21.24, a P/E/G ratio of 2.73 and a beta of 0.97.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.